An Open-label, Multi-center Protocol for Patients Who Have Completed a Previous Novartis Sponsored Remibrutinib Study and Are Judged by the Investigator to Benefit From Continued Treatment With Remibrutinib.

Multi-center, open-label roll-over post-trial access protocol to provide remibrutinib treatment and collect long-term safety for up to three years for participants who are currently receiving remibrutinib treatment in a Novartis-sponsored study, who are benefiting from treatment with remibrutinib, and are unable to access remibrutinib treatment outside of a clinical study.

Start Date10 Apr 2026

Sponsor / Collaborator

Novartis Pharmaceuticals Canada, Inc.

NCT07222956

/ Not yet recruitingPhase 2IIT

An Open-label, Single-center Study of Remibrutinib Using Ultra High-field (7T) MR Imaging in Relapsing or Progressive MS (RemiSeven)

The study is an investigator-run, study following participants for 2 years with twice-daily remibrutinib. MRI is the main endpoint. Safety, tolerability, and efficacy are secondary endpoints. Approximately 20 participants with relapsing or progressive forms of MS will be recruited.

Start Date01 Apr 2026

Sponsor / Collaborator

The Cleveland Clinic Foundation

[+1]

NCT07225504

/ RecruitingPhase 3

A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Remibrutinib in Patients With Secondary Progressive Multiple Sclerosis

The purpose of this study is to provide efficacy and safety data for remibrutinib in patients with secondary progressive multiple sclerosis (SPMS)

Start Date11 Nov 2025

Sponsor / Collaborator

Novartis Pharmaceuticals Canada, Inc.

100 Clinical Results associated with Remibrutinib

100 Translational Medicine associated with Remibrutinib

100 Patents (Medical) associated with Remibrutinib

Literatures (Medical) associated with Remibrutinib

01 Mar 2026·ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

Emerging IgE and non-IgE targeted therapies for chronic urticaria

Review

Author: Chhiba, Krishan D ; Saini, Sarbjit S

Chronic urticaria affects a significant percent of the global population and carries a higher burden of unmet medical need. Current standard-of-care includes antihistamines and omalizumab, but omalizumab is not effective in all patients and has not been found to induce long-term disease remission. This review evaluates the diverse therapeutic pipeline spanning IgE-based and non-IgE-based mast cell targeting strategies, including recent clinical data. The therapeutic landscape has expanded rapidly with multiple mechanisms under investigation. IgE-targeted approaches include omalizumab biosimilars, with CT-P39 having received Food and Drug Administration (FDA) approval. Dupilumab received FDA approval for antihistamine-refractory chronic spontaneous urticaria supporting the targeting of type 2 cytokines, interleukin-4, and interleukin-13, in this disease. Bruton's tyrosine kinase inhibitors have promise, with remibrutinib receiving FDA approval and demonstrating significant reductions in UAS7 in phase 3 trials. c-Kit (c-Kit or KIT) inhibition with barzolvolimab demonstrates robust efficacy with sustained effects post-treatment. Finally, Janus kinase inhibitors, Mas-related G protein-coupled receptor X2 antagonists, and other novel mechanisms are advancing through clinical trials. Although some programs have been discontinued due to safety concerns or lack of efficacy such as fenebrutinib (Bruton's tyrosine kinase inhibitor), THB001 (c-Kit inhibitor), EP262 (Mas-related G protein-coupled receptor X2 antagonist), tezepelumab (anti-TSLP), and lirentelimab and AK006 (sialic acid binding immunoglobulin-like lectin-targeting agents), these studies have informed many of the other positive studies. In summary, in the last year, we have seen the chronic urticaria pipeline mature with multiple phase 3 programs and new approvals representing diverse mechanisms of action. Nevertheless, significant therapeutic gaps persist for omalizumab-refractory disease and chronic-inducible urticaria.

01 Mar 2026·JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Mechanistic insights into petechiae observed with remibrutinib therapy in chronic spontaneous urticaria

Letter

Author: Fein, Michael ; Lazarowitz, Raquel ; Netchiporouk, Elena ; Mosnaim, Giselle ; Nikonova, Anna

01 Mar 2026·DRUGS

Remibrutinib: First Approval

Review

Author: Fung, Simon

Remibrutinib (Rhapsido^®) is an orally administered, selective Bruton's tyrosine kinase (BTK) inhibitor being developed by Novartis for the treatment of chronic spontaneous urticaria (CSU) as well as other immune-mediated disorders. On 30 September 2025 remibrutinib received its first approval in the USA for treatment of CSU in adult patients who remain symptomatic despite H₁-antihistamine treatment. It has subsequently been approved for use in the same indication in China and is under regulatory review in the EU and Japan. This article summarises the milestones in the development of remibrutinib leading to this first approval for CSU in adult patients who remain symptomatic despite H₁-antihistamine treatment.

108

News (Medical) associated with Remibrutinib

23 Mar 2026

·www.biospace.com

Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026

New Rhapsido ® REMIX-1 & -2 pooled analysis on symptom control as early as week 1 in chronic spontaneous urticaria (CSU) to be presented Long-term Cosentyx ® data build on extensive body of evidence supporting continuous use in hidradenitis suppurativa (HS) and psoriasis Additional Cosentyx data in HS include indirect comparison of efficacy and safety vs bimekizumab Basel, March 23, 2026 – Novartis will present data from more than 20 abstracts from its growing immunology portfolio at this year’s American Academy of Dermatology (AAD) Annual Meeting. Presentations include new Rhapsido ® (remibrutinib) data highlighting changes in daily itch and hives severity scores at week 1 in patients with chronic spontaneous urticaria (CSU), an indirect comparison on Cosentyx ® (secukinumab) safety and flare prevention for patients with hidradenitis suppurativa (HS) vs. bimekizumab, as well as 4- and 5-year efficacy data from pivotal trials in HS and psoriasis, respectively. “Novartis data at this year’s AAD build on the robust body of evidence for the use of Rhapsido and Cosentyx in their approved dermatological indications,” said Angelika Jahreis, Global Head, Immunology Development, Novartis. “These presentations also demonstrate the strength of our immunology portfolio and our ongoing efforts to help patients manage chronic diseases that significantly impact their lives and overall well-being.” Key abstracts accepted by AAD include: Molecule/disease state Abstract title Abstract number/ presentation details Rhapsido ® (remibrutinib) CSU Early symptom improvement with remibrutinib in chronic spontaneous urticaria: Daily Itch Severity Scores and Hives Severity Scores from phase 3 REMIX-1/-2 studies Abstract #71668 e-Poster & Oral Presentation March 27, 3:15 pm MT Design of the REASSERT Study: A prospective, multi-country, noninterventional effectiveness and safety study evaluating remibrutinib in patients worldwide with chronic spontaneous urticaria (CSU) Abstract #72973 e-Poster March 27 Burden of disease Urticaria Voices: Treatment patterns and disease control in patients with self-reported chronic inducible urticaria Abstract #75145 e-Poster March 27 Cosentyx ® (secukinumab) HS Flare prevention and safety of secukinumab vs bimekizumab in hidradenitis suppurativa: A matched adjusted indirect comparison analysis of Phase 3 trials Abstract #76852 e-Poster & Oral Presentation Mar 27, 1:45 pm MT Designing a secukinumab dosing regimen in adolescents with moderate to severe hidradenitis suppurativa using model-informed drug development Abstract #74494 e-Poster & Oral Presentation March 28, 2:00 pm MT Four-year efficacy of continuous secukinumab in SUNSHINE/SUNRISE core and extension trials on hidradenitis suppurativa (HS) lesions Abstract #75099 e-Poster March 27 Psoriatic arthritis Effectiveness of Secukinumab in Preventing Psoriatic Arthritis in Patients With Moderate to Severe Psoriasis Abstract #73859 e-Poster & Oral Presentation March 28, 11:45 am MT Impact of Disease Duration on the Treatment Effect of Secukinumab in the Prevention of Psoriatic Arthritis in Patients with Moderate to Severe Psoriasis: A 5-year Pooled Analysis of the ERASURE, FIXTURE and SCULPTURE Studies Abstract #74500 e-Poster & Oral Presentation March 28, 2:05 pm MT About Novartis Immunology At Novartis, we’re advancing bold science with the goal of bringing relief and a renewed sense of hope to people living with autoimmune diseases. Building on our legacy of first-in-class innovation across rheumatology, dermatology and allergy, and a diverse industry-leading pipeline, we’re committed to shaping what’s next in Immunology. Product Information For full prescribing information, including approved indications and important safety information about marketed products, please visit . Disclaimer This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. About Novartis Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 300 million people worldwide. Reimagine medicine with us: Visit us at and connect with us on LinkedIn , Facebook , X/Twitter and Instagram . # # # Novartis Media Relations E-mail: media.relations@novartis.com Novartis Investor Relations Central investor relations line: +41 61 324 7944 E-mail: investor.relations@novartis.com

Phase 3AACR

02 Mar 2026

·www.fiercebiotech.com

Roche reports another phase 3 multiple sclerosis win, but deaths add to safety questions

Safety will be a focus once fenebrutinib is in front of regulators.\n A second phase 3 study of Roche’s fenebrutinib in relapsing multiple sclerosis (RMS) has hit its primary endpoint, positioning the company to submit the BTK inhibitor for approval. But the discovery that more patients died on fenebrutinib than on the control drug has spurred further analyses by Roche.The Swiss drugmaker reported a phase 3 win for fenebrutinib over Sanofi\'s Aubagio in RMS in November. In that study, Roche linked its drug candidate to a 59% reduction in the annualized relapse rate (ARR) compared to Aubagio. Roche replicated the success on Monday, reporting a 51% reduction in ARR over Aubagio in its other phase 3 RMS trial.Both studies linked fenebrutinib to statistically significant reductions in brain lesions, and all progression endpoints trended in favor of the BTK inhibitor. With Roche posting a phase 3 win in primary progressive MS last year, the company believes it has the data to support filings with regulatory authorities. Safety will be a focus once fenebrutinib is in front of regulators. The FDA rejected Sanofi’s request for approval of another BTK inhibitor, tolebrutinib, late last year over the risk of severe drug-induced liver injury. After reviewing the FDA decision, Guggenheim Securities analysts said in a note to investors that Roche will “face a high bar in establishing a favorable risk/reward” for fenebrutinib. The prediction reflected potential cases of Hy’s Law—which relates to liver injury—and elevated liver enzymes. Roche said there was one Hy’s Law case each in the fenebrutinib and Aubagio arms in the newly reported RMS trial. Both cases were asymptomatic and resolved after study drug discontinuation. Roche hasn’t seen any other Hy’s Law cases across the fenebrutinib clinical development program.In guidance on drug-induced liver injury, the FDA said “finding one Hy’s Law case in the clinical trial database is worrisome.” A second case would cause deeper concerns. The FDA views two Hy’s Law cases as highly predictive that a therapy has the potential to cause severe drug-induced liver injury when given to a larger population. Across the two RMS trials, eight patients on fenebrutinib died compared to one death in the Aubagio arms. Roche said the fenebrutinib deaths had various causes and happened at different points in treatment. The drugmaker is analyzing the data to better understand the findings. Roche will share full data from the RMS trials at an event in April.The safety concerns facing Roche’s fenebrutinib and Sanofi’s tolebrutinib create potential opportunities for Novartis, which is developing a rival BTK inhibitor. Novartis has won approval for the drug, Rhapsido, in chronic spontaneous urticaria without triggering liver safety concerns. The drugmaker is now closing in on data from phase 3 trials comparing its candidate to Sanofi’s Aubagio in RMS.

Phase 3Clinical ResultDrug Approval

02 Mar 2026

·allsci.com

LongBio's LP-003 outperforms omalizumab in phase II chronic spontaneous urticaria trial

China-based LongBio Pharma (Suzhou) Co., Ltd announced positive topline results from a Phase II trial of LP-003, its next-generation anti-IgE antibody, in patients with chronic spontaneous urticaria (CSU) who remained symptomatic despite H1 antihistamine treatment. The data, presented as a late-breaking poster at the 2026 AAAAI Annual Meeting, showed LP-003 achieved statistically superior outcomes compared with omalizumab (Xolair) across two key efficacy endpoints — a result that, if confirmed in Phase III, could position the molecule as the first new anti-IgE therapy to reach the market in more than two decades. The trial (NCT06228560, CTR20233300) was a multicenter, randomized, double-blind, placebo- and active-controlled study conducted in China. A total of 202 adults with CSU were enrolled and assigned to one of five arms: LP-003 at 100 mg every four weeks (Q4W), LP-003 200 mg Q4W, LP-003 200 mg every eight weeks (Q8W), omalizumab 300 mg Q4W, or placebo. The treatment duration was 24 weeks. The primary endpoint was the proportion of patients achieving a weekly Urticaria Activity Score of zero (UAS7=0) — denoting complete absence of hives and itch — at Week 12, with the top rate of 66.7% achieved in the LP-003 200 mg Q8W arm, and 57.5% in the LP-003 200 mg Q4W arm, versus 43.6% in the omalizumab arm, and 10.8% in the placebo arm. The comparison between LP-003 200 mg Q8W and omalizumab reached statistical significance (p=0.0405). A second key efficacy measure, the least-squares mean change from baseline in UAS7 at Week 12, was −26.63 for LP-003 200 mg Q8W versus −21.85 for omalizumab (p=0.0137). By Week 4, complete remission rates across LP-003 groups ranged from 35% to 35.9%, suggesting a fast onset of action relative to the comparator. LongBio described the safety profile as favorable, though no quantitative adverse-event data were disclosed in the topline release. The company said a Phase III trial for CSU in China is expected to begin in H1 2026. Separately, LP-003’s lead indication is seasonal allergic rhinitis (SAR), for which a Phase III trial in China has completed enrollment and a Biologics License Application (BLA) submission to China’s National Medical Products Administration (NMPA) is planned in or before Q3 2026. If approved, LP-003 would become the first and only innovative anti-IgE drug to be launched globally in over 20 years since the approval of omalizumab. LP-003 is a monoclonal antibody that neutralizes free immunoglobulin E (IgE), the same target as omalizumab. By binding circulating IgE, the antibody prevents it from engaging the high-affinity IgE receptor FcεRI on mast cells and basophils, reducing degranulation and the downstream release of histamine and other mediators that drive wheals and pruritus. Over time, anti-IgE therapy also downregulates FcεRI surface expression, further dampening the allergic cascade. LongBio states that LP-003 has 860-fold greater IgE binding affinity and 30-fold higher blocking activity than omalizumab, along with a longer half-life. The CSU treatment landscape has evolved in the past two years. Key competing assets include: Novartis’s remibrutinib (LOU064), an oral Bruton’s tyrosine kinase (BTK) inhibitor that has completed Phase III trials in CSU and received a positive CHMP opinion for EU approval. Remibrutinib acts downstream of IgE signaling, inhibiting mast cell and basophil activation directly, and represents a mechanistically distinct oral alternative. Sanofi/Regeneron’s dupilumab (Dupixent), an IL-4 receptor alpha antibody already approved for multiple type 2 inflammatory conditions, which has received a positive CHMP recommendation for CSU in children aged 2–11 years and is being studied in broader CSU populations. United BioPharma’s UB-221, another anti-IgE monoclonal antibody in Phase II for CSU, which targets IgE with a reported CD23-mediated IgE downregulation mechanism. Novartis’s ligelizumab (QGE031), a high-affinity anti-IgE antibody that completed Phase III in CSU but whose development extension was terminated, leaving its forward trajectory in this indication unclear.

Phase 2Phase 3Clinical ResultDrug ApprovalImmunotherapy

100 Deals associated with Remibrutinib

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Chronic Urticaria	United States	Novartis Pharmaceuticals Corp.	30 Sep 2025

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Myasthenia Gravis	NDA/BLA	Canada	Novartis Pharmaceuticals Canada, Inc.	01 Sep 2025
Multiple Sclerosis, Secondary Progressive	Phase 3	United States	Novartis Pharmaceuticals Canada, Inc.	11 Nov 2025
Multiple Sclerosis, Secondary Progressive	Phase 3	China	Novartis Pharmaceuticals Canada, Inc.	11 Nov 2025
Multiple Sclerosis, Secondary Progressive	Phase 3	Argentina	Novartis Pharmaceuticals Canada, Inc.	11 Nov 2025
Multiple Sclerosis, Secondary Progressive	Phase 3	Australia	Novartis Pharmaceuticals Canada, Inc.	11 Nov 2025
Multiple Sclerosis, Secondary Progressive	Phase 3	Bulgaria	Novartis Pharmaceuticals Canada, Inc.	11 Nov 2025
Multiple Sclerosis, Secondary Progressive	Phase 3	Canada	Novartis Pharmaceuticals Canada, Inc.	11 Nov 2025
Multiple Sclerosis, Secondary Progressive	Phase 3	Colombia	Novartis Pharmaceuticals Canada, Inc.	11 Nov 2025
Multiple Sclerosis, Secondary Progressive	Phase 3	Czechia	Novartis Pharmaceuticals Canada, Inc.	11 Nov 2025
Multiple Sclerosis, Secondary Progressive	Phase 3	France	China Novartis Institutes for BioMedical Research Co., Ltd.	11 Nov 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05048342 (BISCUIT, Pubmed \| Dermatol Ther (Heidelb))	Phase 3	Chronic Urticaria	71	Remibrutinib 25 mg (Chronic Spontaneous Urticaria + Japanese)	pliynjiyyw(ymlpovjefr) = uurhobwesj jggtnhehcc (bshjjtmgpv ) View more	Positive	19 Feb 2026
NCT05795153 (CTgov)	Phase 3	Chronic Urticaria	144	LOU064	wdgxntbglp(cqredukayt) = pmcezdtdio ytjwbbiqgu (aubhbecbtg, yupdzzrhya - tfmslzooed) View more	-	30 Apr 2025
NCT05032157 \| NCT05030311 (REMIX-2, NEWS \| Pubmed) Manual	Phase 3	Urticaria	-	remibrutinib (REMIX-1)	nzbnwqeeqc(kbajwxygaz) = ovosrpahva uxouqmlfus (wikvvmcogj, 0.7) View more	Positive	11 Mar 2025
				placebo (REMIX-1)	nzbnwqeeqc(kbajwxygaz) = vugdmhdgig uxouqmlfus (wikvvmcogj, 1.0) View more
REMIX-1 (AAD2025)	Phase 3	Chronic Urticaria	753	Remibrutinib	jtyfwmznzb(gmxyiwdynm) = neebceuuot svobcngxlu (sexwlkznsz ) View more	Positive	07 Mar 2025
				Remibrutinib	jtyfwmznzb(gmxyiwdynm) = dtywdtjatk svobcngxlu (sexwlkznsz ) View more
NCT03827798 (AAD2025)	Phase 2	Hidradenitis Suppurativa	77	Remibrutinib 25mg	wyurellslx(isihfqdhhj) = ljpdrunxow aobbmexvtb (uwndpemsxt ) View more	Positive	07 Mar 2025
				Remibrutinib 100mg	wyurellslx(isihfqdhhj) = irehqvkmof aobbmexvtb (uwndpemsxt ) View more
REMIX-1 (AAD2025)	Phase 3	Chronic Urticaria	753	Remibrutinib 25 mg (REMIX-1)	rmbshdzsue(mgqcxycmyy) = qkdmwqzajo dtmkbzxmch (mtbanxaxmm, 0.3) View more	Positive	07 Mar 2025
				Remibrutinib 25 mg (REMIX-2)	rmbshdzsue(mgqcxycmyy) = zsxdxdsxrn dtmkbzxmch (mtbanxaxmm, 0.3) View more
NCT05032157 \| NCT05030311 (REMIX-1 and REMIX-2, Pubmed \| N Engl J Med)	Phase 3	Chronic Urticaria Bruton's tyrosine kinase	-	Remibrutinib 25 mg twice daily	yayrxnzxlz(qheyubuwkd) = gjjridfwey mkgkxgzvda (emqdperweo ) View more	Positive	06 Mar 2025
				Placebo	yayrxnzxlz(qheyubuwkd) = aahqassteo mkgkxgzvda (emqdperweo ) View more
NCT05030311 (REMIX-1 \| REMIX-1 and REMIX-2, CTgov)	Phase 3	Chronic Urticaria	470	LOU064 (LOU064 25mg b.i.d.)	rgynigoyzh(sorvvtmjhm) = hfztqzhaaw sbwpldczir (tjssrhbysp, 0.716) View more	-	02 Dec 2024
				Placebo+LOU064 (Placebo)	rgynigoyzh(sorvvtmjhm) = kmsomqgich sbwpldczir (tjssrhbysp, 0.980) View more
NCT05048342 (BISCUIT, CTgov)	Phase 3	Chronic Urticaria	71	LOU064	lncmhkxpyw = ijcclxuwak dmjxmfdodv (totqeoasfy, oegzhroshy - smulcdvaux) View more	-	22 Nov 2024
NCT04035668 (LOUiSSe, ACR2024)	Phase 2	anti-Ro60-positive	346	remibrutinib	lgragwlfia(sdwyrmqtta) = ykxnzdohkn ywufwearwm (ygkbvwptfa ) View more	Positive	10 Nov 2024
				Placebo	lgragwlfia(sdwyrmqtta) = mpwlchcvpr ywufwearwm (ygkbvwptfa ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Remibrutinib

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation